Merck to buy Harpoon for $680 million to step up cancer portfolio
HQ Team January 8, 2024: Merck & Co., will acquire Harpoon Therapeutics, Inc., for $680 million to expand its cancer drug portfolio —.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team January 8, 2024: Merck & Co., will acquire Harpoon Therapeutics, Inc., for $680 million to expand its cancer drug portfolio —.
HQ Team July 29, 2023: Merck & Co., Inc., announced it has met one of the primary goals during a late-stage trial of.
Verge Genomics, backed by Eli Lilly and Merck & Co., announced it had dosed a human during clinical trials with a drug discovered.